AtaiBeckley Inc Dossier - Source-backed chat

AtaiBeckley Inc

ATAINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.37

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.35Price as of 10 Sep 2026

Data confidenceNot applicable

Market Cap $2.7B

Enterprise Value $2.7B

Shares Outstanding 370.9M diluted

Moat Rating None

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AtaiBeckley (NASDAQ: ATAI) represents a premier, clinical-stage biopharmaceutical vehicle positioned to lead the commercialization of rapid-acting, short-duration psychedelic medicines. Formed via the strategic combination of atai Life Sciences and Beckley Psytech in late 2025, the company boasts a highly differentiated pipeline designed to fit seamlessly into existing interventional psychiatry infrastructure. Its lead asset, BPL-003 (intranasal 5-MeO-DMT), holds FDA Breakthrough Therapy designation and is entering Phase 3 trials with a highly competitive 2-hour in-clinic discharge profile. Backed by a robust cash position of $209.9 million that extends its runway into 2029, AtaiBeckley is well-capitalized to achieve major clinical readouts without near-term dilution risk.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.45

Mean target$9.09

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.45

The bear case is triggered by clinical or regulatory setbacks, such as safety concerns, failure to meet primary endpoints in the VLS-01 Phase 2b trial, or enrollment delays in the BPL-003 Phase 3 program. Additionally, broader regulatory headwinds or negative class-wide FDA decisions on psychedelic therapies could depress sector valuations, forcing the stock down to its cash-backed floor.

Base CaseCentral scenario

$9.09

Matches the consensus mean

The base case projects that AtaiBeckley successfully initiates and advances its parallel Phase 3 trials for BPL-003, while delivering positive, competitive Phase 2b data for VLS-01 in late 2026. The company maintains its disciplined cash burn, preserving its runway into 2029. Valuation is driven by steady clinical progress and strong analyst support, aligning with the consensus target of approximately $14.00 to $16.00 as the pipeline is progressively de-risked.

Bull CaseUpside scenario

$16.00

The bull case assumes flawless execution of the BPL-003 Phase 3 ReConnection program and positive Phase 2b topline data for VLS-01 in late 2026. Under this scenario, BPL-003 establishes itself as a best-in-class rapid-acting antidepressant with a highly scalable 90-to-120-minute clinic turnaround, matching or exceeding the commercial success of Spravato. Strong clinical execution and favorable regulatory shifts in the psychedelic space drive institutional capital inflows, pushing the stock toward the high end of analyst expectations.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated, short-duration clinical profile (BPL-003 allows patient discharge within 2 hours, optimizing clinic throughput compared to 8-hour psilocybin alternatives).
Robust balance sheet with $209.9 million in cash as of Q1 2026, providing a clear runway into early 2029 and covering key Phase 3 milestones.
FDA Breakthrough Therapy designation for lead asset BPL-003, validating its therapeutic potential and streamlining the regulatory pathway.
Strong institutional backing and strategic alignment following the successful merger of atai Life Sciences and Beckley Psytech.

Key Investment Risks

High clinical development risk inherent to neuropsychiatric and psychedelic-based drug candidates.
Regulatory uncertainty surrounding the approval and commercial scheduling of novel psychedelic compounds.
Commercial execution risks, including the need to integrate therapies into specialized interventional psychiatry clinics.

Thesis Invalidation Triggers

Failure of BPL-003 to meet primary efficacy endpoints in the Phase 3 ReConnection trials.
Severe, unexpected adverse safety events leading to clinical holds by the FDA.
Significant acceleration of cash burn that prematurely shortens the projected runway to below late 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.